Kornitzer Capital Management Inc. KS Sells 1,900 Shares of STAAR Surgical (NASDAQ:STAA)

Kornitzer Capital Management Inc. KS decreased its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 1.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 162,725 shares of the medical instruments supplier’s stock after selling 1,900 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in STAAR Surgical were worth $3,953,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in STAA. JPMorgan Chase & Co. raised its position in shares of STAAR Surgical by 411.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after acquiring an additional 172,779 shares during the last quarter. American Capital Management Inc. increased its position in shares of STAAR Surgical by 42.9% in the 3rd quarter. American Capital Management Inc. now owns 512,813 shares of the medical instruments supplier’s stock valued at $19,051,000 after buying an additional 154,037 shares in the last quarter. KBC Group NV increased its position in shares of STAAR Surgical by 5,700.9% in the 4th quarter. KBC Group NV now owns 96,585 shares of the medical instruments supplier’s stock valued at $2,346,000 after buying an additional 94,920 shares in the last quarter. Barclays PLC increased its position in shares of STAAR Surgical by 349.4% in the 3rd quarter. Barclays PLC now owns 91,707 shares of the medical instruments supplier’s stock valued at $3,406,000 after buying an additional 71,301 shares in the last quarter. Finally, GSA Capital Partners LLP increased its position in shares of STAAR Surgical by 134.8% in the 3rd quarter. GSA Capital Partners LLP now owns 118,789 shares of the medical instruments supplier’s stock valued at $4,413,000 after buying an additional 68,196 shares in the last quarter. Institutional investors own 96.70% of the company’s stock.

Insiders Place Their Bets

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 23,000 shares of STAAR Surgical stock in a transaction dated Wednesday, December 18th. The stock was bought at an average cost of $24.33 per share, for a total transaction of $559,590.00. Following the purchase, the insider now directly owns 10,848,631 shares in the company, valued at approximately $263,947,192.23. This represents a 0.21 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. In the last 90 days, insiders bought 402,024 shares of company stock worth $6,936,904. Corporate insiders own 1.00% of the company’s stock.

STAAR Surgical Trading Up 8.3 %

STAA stock opened at $16.63 on Wednesday. The stock has a 50-day moving average price of $22.95 and a two-hundred day moving average price of $28.47. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68.

Wall Street Analyst Weigh In

A number of research firms recently commented on STAA. Mizuho cut shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $45.00 to $17.00 in a research report on Wednesday, February 12th. Canaccord Genuity Group lowered their price objective on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a research report on Wednesday, February 12th. Stifel Nicolaus lowered their price objective on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, February 12th. Finally, StockNews.com cut STAAR Surgical from a “hold” rating to a “sell” rating in a report on Thursday, February 13th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $26.86.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.